The Cancer Letter

Inside information on cancer research and drug development

Vol.
35
No.
6
June 29, 2012Jun 29, 2012
Free
DOWNLOAD THE PDF

Phase III Data of Antibody-Drug Conjugate Shows PFS Increase in HER2+ Disease

Continous Hormone Therapy Superior To Intermittent In 17-Year SWOG Study

Phase III Afatinib Trial Met Primary Endpoint In Stage IIIb or IV Cancer with EGFR Mutation

Phase III Regorafenib Trial Meets PFS Primary Endpoint

Radium-233 Dichloride Increased Overall Survival in Phase III Trial

Zytiga Plus Prednisone Shows Improvement in PFS and OS Over Prednisone Alone

Nexavar Phase III Trial Fails To Meet Primary Endpoint

Alimta/Cisplatin Chemotherapy Increased Overall Survival

New Carfilzomib Combination Produces Near Remissions

Trial Data: No Benefit In Adding Perifosine to Capecitabine

Blinatumomab Demonstrates High Response Rate in ALL

MET Inhibitor Improved Time To Progression by 56 Percent

NCI-Approved CTEP Trials For The Month of June

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account